SCHEMBL108359

SCHEMBL108359

CC(C)CC(O)C(O)CC(C)C

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.50
ALDH1A1 P00352 3/20 0.50
MAPK1 P28482 1/20 0.50
LMNA P02545 1/20 0.39
ANPEP P15144 5/20 0.38
TDP1 Q9NUW8 1/20 0.38
RNPEP Q9H4A4 1/20 0.36
SLC7A5 Q01650 1/20 0.36
LAP3 P28838 2/20 0.35
ERAP1 Q9NZ08 2/20 0.35
ERAP2 Q6P179 1/20 0.33
TRPV1 Q8NER1 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
NFKB1 P19838 1/20 0.32
THPO P40225 1/20 0.32
TRPA1 O75762 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL108666 0.87 TSHR (0.44) TSHRALDH1A1MAPK1ANPEPTDP1
SCHEMBL12042669 0.87 TSHR (0.44) TSHRALDH1A1MAPK1ANPEPTDP1
SCHEMBL12042668 0.87 TSHR (0.44) TSHRALDH1A1MAPK1ANPEPTDP1
SCHEMBL12042667 0.87 TSHR (0.44) TSHRALDH1A1MAPK1ANPEPTDP1
SCHEMBL9740003 0.87 TSHR (0.47) TSHRALDH1A1MAPK1LMNAANPEP
SCHEMBL7325421 0.87 TSHR (0.44) TSHRALDH1A1MAPK1ANPEPTDP1
SCHEMBL11890306 0.85
SCHEMBL108574 0.85
SCHEMBL12346197 0.85 LMNA (0.39) TSHRALDH1A1MAPK1LMNAANPEP
SCHEMBL11890515 0.85

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463374-A2 Isolated alcohol dehydrogenase enzymes and uses thereof Bio Architecture Lab, Inc. (US) 2012-06-13 EP claimed
EP-2195440-A2 BIOFUEL PRODUCTION Bio Architecture Lab, Inc. (US) 2010-06-16 EP claimed
US-20090155873-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-18 US claimed
US-20090139134-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-04 US claimed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO claimed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO claimed
EP-3230463-B2 RAPID PRETREATMENT APALTA PATENTS OUE (EE) 2025-07-16 EP disclosed
US-20240425893-A1 RAPID PRETREATMENT Apalta Patents OÜ (EE) 2024-12-26 US disclosed
US-12054761-B2 Rapid pretreatment Apalta Patents OÜ (EE) 2024-08-06 US disclosed
US-11834463-B2 High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders Technische Universität Darmstadt (DE) 2023-12-05 US disclosed
US-11821047-B2 High pressure zone formation for pretreatment Apalta Patent OÜ (EE) 2023-11-21 US disclosed
US-20230295678-A1 RAPID PRETREATMENT Apalta Patents OÜ (EE) 2023-09-21 US disclosed
US-20230212185-A1 HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS Technische Universität Darmstadt (DE) 2023-07-06 US disclosed
WO-2009097346-A2 ISOLATED ALCOHOL DEHYDROGENASE ENZYMES AND USES THEREOF BIO ARCHITECTURE LAB, INC. (US) 2009-08-06 WO disclosed
US-20090155873-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-18 US disclosed
US-20090139134-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-04 US disclosed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO disclosed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO disclosed
US-4466903-A Unsaturated 1,3-dioxolane stabilized with aliphatic aldehyde hydrazone PPG INDUSTRIES, INC. (US) 1984-08-21 US disclosed
US-4418231-A ACID ACCEPTING 2-ALKYLIDENE-1,3-DIOXOLANES IN TRICHLOROETHYLENE AND/OR METHYLCHLOROFORM PPG INDUSTRIES, INC. (US) 1983-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212185-A1 HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS FKBP1B, FKBP5, FKBP1A TSHR 2318/4885ALDH1A1 4075/4885MAPK1 1377/4885
US-11834463-B2 High affinity macrocyclic FKB51-inhibitors for treatment of psychiatric disorders FKBP1B, FKBP5, FKBP1A TSHR 2318/4885ALDH1A1 4075/4885MAPK1 1377/4885
US-20090139134-A1 BIOFUEL PRODUCTION MGAM, DCXR, MANBA TSHR 3426/4885ALDH1A1 753/4885MAPK1 2216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.